The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that ...

Wa'el Hashad Wa'el Hashad, CEO, Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

Two posters were presented by Annovis' President and CEO, Dr. Maria Maccecchini, focusing on the company's lead drug candidate bunta ...

Third Quarter, Recent Business Highlights and Upcoming Milestones Neurodegenerative Diseases Portfolio Alzheimer's Disease PRX012 ... approximately 260 patients in the ASCENT clinical trials Poster ...

Julianna LeMieux and Uduak Thomas discuss their time at the ASHG meeting in Denver and some of the trends that they are ...

The platform presentation entitled, “The MSA Atrophy Index: A Marker of Clinical Progression in Multiple System Atrophy”, was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...